Melanoma
Biological License Application to be Filed for Stage II Melanoma Vaccine
Published in Cancer Weekly, October 24th, 2000
The biological license application (BLA) will be based predominantly on data from the recently completed Phase III study of the use of Melacine vaccine for the treatment of Stage II melanoma, which started enrollment in April of 1992 and has followed patients through January of 2000. The filing will also contain data following the same group of patients through January of 2001.
The results of this study, conducted by the former Ribi Immunochem Research, Inc., (acquired...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2000-10-24)
More Articles from Cancer Weekly
- Cancer Symptom Distress
Thirteen "Core" Factors Account for Majority of Symptoms and Side Effects - Colorectal Cancer
New First-Line Chemotherapy Treatment Developed for Metastatic Disease - Testicular Cancer
High-Dose Chemotherapy Effective in Patients with Recurrent Disease - Cancer Therapies
Inhaled Isotretinoin Can Lower Risk of Lung and Aerodigestive Cancers While Minimizing Toxicity - Colorectal Cancer
Mutations in Newly Discovered Gene Result in Defective Mismatch Repair - Cutaneous Melanoma
Long-Term Trials Indicate that Smaller Resection Margins Don't Compromise Results - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
